SCHEDULE: Lynx1 Capital Discloses 7.8% Stake in Korro Bio

Lynx1 Capital Management LP and Weston Nichols have reported a 7.8% beneficial ownership stake in Korro Bio, Inc. common stock.

Summary

• Lynx1 Capital Management LP and Weston Nichols collectively reported beneficial ownership of 733,633 shares of Korro Bio, Inc. Common Stock.
• This ownership represents 7.8% of Korro Bio, Inc.'s outstanding Common Stock.
• The percentage is calculated based on 9,417,295 shares of Common Stock outstanding as of November 10, 2025, as reported in the Company's Form 10-Q.
• The filing is a Schedule 13G, indicating a passive investment intent, not for the purpose of changing or influencing control of the issuer.
• Lynx1 Capital Management LP acts as the investment manager to Lynx1 Master Fund LP, which directly holds the shares.
• Weston Nichols is the sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP.

Sentiment

Score: 5

Explanation: Neutral, as this is a standard regulatory disclosure of beneficial ownership and does not contain operational or financial performance updates, nor does it indicate an activist stance.

Positives

• The disclosure of a significant 7.8% stake by an institutional investor like Lynx1 Capital Management LP could be interpreted by the market as a vote of confidence in Korro Bio, Inc.

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor and does not provide specific insights into broader industry trends or competitive positioning of Korro Bio, Inc.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor holding a 7.8% stake, which may be viewed as a positive signal of institutional interest.

Key Dates

Keywords

Korro Bio, Lynx1 Capital Management, Weston Nichols, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor